The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects

References

• World Obesity Federation. World Obesity Atlas 2023; 2023. Available from: https://data.worldobesity.org/publications/?cat=19. Accessed July 24, 2023.
   Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocr Pract. 2016;22:1–203. doi:10.4158/EP161365.GL
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161. doi:10.2337/diacare.27.1.155
   PubMed Web of Science ®Google Scholar
• Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470–512. doi:10.1124/pr.108.000604
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gasbjerg LS, Rosenkilde MM. The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. 2021;162(7):bqab065. doi:10.1210/endocr/bqab065
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Pedrosa MR, Franco DR, Gieremek HW, et al. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: what Have We Achieved so Far? Curr Atheroscler Rep. 2022. doi:10.1007/s11883-022-01062-2
   PubMed Web of Science ®Google Scholar
• Edwards KL, Stapleton M, Weis J, Irons BK. An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists. Diabetes Technol Ther. 2012;14(10):951–967. doi:10.1089/dia.2012.0098.edw
   PubMed Web of Science ®Google Scholar
• Tschöp MH, Finan B, Clemmensen C, et al. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metab. 2016;24(1):51–62. doi:10.1016/j.cmet.2016.06.021
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled Phase 2 trial. Lancet. 2018;392(10160):2180–2193. doi:10.1016/S0140-6736(18)32260-8
   PubMed Web of Science ®Google Scholar
• FDA. FDA Product Label - Mounjaro. Mounjaro. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000lbl.pdf. Accessed September 1, 2022.
   Google Scholar
• Wegovy Public Assessment Report. EMA. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy. Accessed January 18, 2023.
   Google Scholar
• Zepbound FDAPL; 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf. Accessed December 29, 2023.
   Google Scholar
• Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388–396. doi:10.1210/clinem/dgaa863
   PubMed Web of Science ®Google Scholar
• Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. doi:10.1172/jci.insight.140532
   PubMed Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metabol. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009
   PubMed Web of Science ®Google Scholar
• Wang L. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: comparing Residues Between Tirzepatide, GLP-1, and GIP. Drug Des Devel Ther. 2022;16:1547–1559. doi:10.2147/DDDT.S358989
   PubMed Web of Science ®Google Scholar
• FDA Clinical Pharmacology Review(s). Center for Drug Evaluation and Research. Application Number: 215866Orig1S000. Tirzepatide. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf. Accessed September 27, 2023.
   Google Scholar
• Urva S, Quinlan T, Landry J, Martin J, Loghin C. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2021;60(8):1049–1059. doi:10.1007/s40262-021-01012-2
   PubMed Web of Science ®Google Scholar
• Urva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2022. doi:10.1007/s40262-022-01140-3
   PubMed Web of Science ®Google Scholar
• SURMOUNT-3 (NCT04657016) information from clinicaltrials.gov. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04657016. Accessed September 27, 2023.
   Google Scholar
• SURMOUNT-4 (NCT04660643). Information from clinicaltrials.gov. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04660643. Accessed September 27, 2023.
   Google Scholar
• SURMOUNT-MMO (NCT05556512). Information from clinicaltrials.gov. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05556512. Accessed September 27, 2023.
   Google Scholar
• SURMOUNT-OSA (NCT05412004). Information from clinicaltrials.gov. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05412004. Accessed September 27, 2023.
   Google Scholar
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023:S014067362301200X. doi:10.1016/S0140-6736(23)01200-X
   Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022:NEJMoa2206038. doi:10.1056/NEJMoa2206038
   Google Scholar
• Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. doi:10.1016/S0140-6736(21)01324-6
   PubMed Web of Science ®Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
   PubMed Web of Science ®Google Scholar
• Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–598. doi:10.1016/S0140-6736(21)01443-4
   PubMed Web of Science ®Google Scholar
• Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–1824. doi:10.1016/S0140-6736(21)02188-7
   PubMed Web of Science ®Google Scholar
• Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: the SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534. doi:10.1001/jama.2022.0078
   PubMed Web of Science ®Google Scholar
• Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623–633. doi:10.1016/S2213-8587(22)00188-7
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):634–644. doi:10.1016/S2213-8587(22)00187-5
   PubMed Web of Science ®Google Scholar
• Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023;29(6):1500–1510. doi:10.1038/s41591-023-02344-1
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Á R. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406. doi:10.1016/S2213-8587(22)00070-5
   PubMed Web of Science ®Google Scholar
• Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy). Diabetes Obes Metab. 2023;25(2):398–406. doi:10.1111/dom.14882
   PubMed Web of Science ®Google Scholar
• Linge J, Neelan IJ, Dahlqvist Leinhard O, et al. Tirzepatide achieves significant weight loss without adverse effects on muscle composition (SURPASS-3 MRI). In: Oral presentation at the Europaean Association for the Study of Diabetes (EASD), 59th EASD annual meeting; 2023. https://cattendee.abstractsonline.com/meeting/10899/presentation/253.
   Google Scholar
• Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–598. doi:10.1038/s41591-022-01707-4
   PubMed Web of Science ®Google Scholar
• Furihata K, Mimura H, Urva S, Oura T, Ohwaki K, Imaoka T. A Phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obesity Metab. 2022;24(2):239–246. doi:10.1111/dom.14572
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: a 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes Obes Metab. 2020;22(6):938–946. doi:10.1111/dom.13979
   PubMed Web of Science ®Google Scholar
• Calderon B, Mullins GR, Hodsdon M, et al. 742-P: antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: analysis of Data from 7 Phase 3 Studies. Diabetes. 2022;71(Supplement_1):742–P. doi:10.2337/db22-742-P
   Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352. doi:10.1016/S0140-6736(11)60205-5
   PubMed Web of Science ®Google Scholar
• Jensterle M, Rizzo M, Haluzík M, Janež A. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: a Narrative Review. Adv Ther. 2022;39(6):2452–2467. doi:10.1007/s12325-022-02153-x
   PubMed Web of Science ®Google Scholar
• Lilly Investors. Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies. Published July 27^th; 2023. Available from: https://investor.lilly.com/news-releases/news-release-details/tirzepatide-demonstrated-significant-and-superior-weight-loss. Accessed August 23, 2023.
   Google Scholar
• Kwan A, Maldonado JM, Wang H, Rasouli N, Wilding J. 719-P: tirzepatide Induces Weight Loss in Patients with Type 2 Diabetes Regardless of Baseline BMI: a Post Hoc Analysis of SURPASS-1 through −5 Studies. Diabetes. 2022;71(Supplement_1):719–P. doi:10.2337/db22-719-P
   Google Scholar
• Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52(2):380–386. doi:10.2337/diabetes.52.2.380
   PubMed Web of Science ®Google Scholar
• Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021;44(3):765–773. doi:10.2337/dc20-1473
   PubMed Web of Science ®Google Scholar
• Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563–574. doi:10.1016/S2213-8587(21)00174-1
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006
   PubMed Web of Science ®Google Scholar
• Gasbjerg LS, Bergmann NC, Stensen S, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. 2020;125:170183. doi:10.1016/j.peptides.2019.170183
   PubMed Web of Science ®Google Scholar
• A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP), NCT05646706. Sponsor: novo Nordisk. Available from: https://clinicaltrials.gov/study/NCT05646706?tab=table. Accessed December 29, 2023.
   Google Scholar
• Huixing L, Di F, Daoquan P. Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Ther. 2023;45(1):17–30. doi:10.1016/j.clinthera.2022.12.006
   PubMed Web of Science ®Google Scholar
• Fudim M, White J, Pagidipati NJ, et al. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: insights From the EXSCEL Trial. Circulation. 2019;140(20):1613–1622. doi:10.1161/CIRCULATIONAHA.119.041659
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
   PubMed Web of Science ®Google Scholar